Takeover of BioXell: Prospectus of Cosmo has been published
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Milan, Italy, 8 December 2009 - As announced on November 18, 2009,Cosmo Pharmaceuticals S.p.A. (SIX Swiss Exchange: COPN),headquartered in Lainate, Italy, has published the offer prospectustoday in which a public tender offer is made to the shareholders ofBioXell S.p.A. (SIX Swiss Exchange: BXLN).The detailed terms of the Offer are set out in Cosmo's offerprospectus of today. The offer prospectus of Cosmo (including thereport of the board of directors of BioXell) can be downloaded atwww.cosmopharmaceuticals.com.About BioXellBioXell is a listed biopharmaceutical company focused on thediscovery and development of drugs that exploit novel mechanisms ofaction. Following the conclusion of its Vitamin D3 related R&Dactivities BioXell has been looking into a number of strategicoptions in line with the demands of its shareholders.BioXell was founded in 2002 as a spin-out from Roche. In June 2006,BioXell listed its shares on the main segment of the SIX SwissExchange. The company is located in Milan, Italy.More information on BioXell can be found at: www.bioxell.comAbout CosmoCosmo is a specialty pharmaceutical company that aims to become aglobal leader in optimised therapies for certain GastrointestinalDiseases. The company's proprietary clinical development pipelinespecifically addresses innovative treatments for IBD, such asUlcerative Colitis and Crohn's Disease, and Colon Infections. Cosmo'sfirst MMX(TM) product that has reached the market is Lialda(TM) /Mezavant®, a treatment for IBD that is licensed globally to Giulianiand Shire Limited. Cosmo's proprietary MMX® technology is at the coreof the company's product pipeline and was developed from itsexpertise in formulating and manufacturing gastrointestinal drugs forinternational clients at its GMP (Good Manufacturing Practice)facilities in Lainate, Italy. The technology is designed to deliveractive ingredients in a targeted manner in the intestines.More information on Cosmo can be found at:www.cosmopharmaceuticals.comFor further information, please contact:BioXell Dynamics Group SAAlvise Sagramoso, Chief Administrative Christophe LampsOfficerTel: +39 (0)2 210 49 550 Tel: +41 (0)22 308 62 22Fax: +39 (0)2 700 59 926 Fax: +41 (0)22 308 62 36alvise.sagramoso(at)bioxell.com cla(at)dynamicsgroup.chThis press release can be downloaded at www.bioxell.com.DisclaimerThis document does not constitute, or form part of, any offer topurchase or sell any shares or other securities and neither it norany part of it shall form the basis of, or be relied upon inconnection with any contract or commitment whatsoever. Any decisionto tender shares must be based on the official offer documents. Thisdocument does also not constitute a pre-announcement or an offeringprospectus pursuant to Swiss laws or any other laws.This press release does not constitute or form part, or all, of anyoffer or invitation to sell or issue, or any solicitation of anyoffer to purchase or subscribe for, any securities, nor shall part,or all, of these materials or their distribution form the basis of,or be relied on in connection with, any contract or investmentdecision in relation to any securities. This press release containsforward-looking statements based on the currently held beliefs andassumptions of the management of BioXell, which are expressed in goodfaith and, in their opinion, reasonable. Forward-looking statementsinvolve known and unknown risks, uncertainties and other factors,which may cause the actual results, financial condition, performance,or achievements of BioXell, or industry results, to differ materiallyfrom the results, financial condition, performance or achievementsexpressed or implied by such forward-looking statements. Given theserisks, uncertainties and other factors, recipients of this documentare cautioned not to place undue reliance on these forward-lookingstatements. BioXell disclaims any obligation to update theseforward-looking statements to reflect future events or developments.http://hugin.info/133681/R/1359717/331499.pdf --- End of Message ---bioXell S.p.Avia Olgettina 58 Milan ItalyWKN: A0J3MW; ISIN: IT0004069933 ; Listed: Main Market in SIX Swiss Exchange;
Datum: 08.12.2009 - 07:00 Uhr
Sprache: Deutsch
News-ID 9353
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 521 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Takeover of BioXell: Prospectus of Cosmo has been published"
steht unter der journalistisch-redaktionellen Verantwortung von
bioXell S.p.A (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
